Newsroom 2004

2004 Releases

Plasma Products Agreement Signed
CSL Limited announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products. More.

CSL Announces Full Year Results
CSL Limited today announced its operating results for the full year ended 30 June 2004. More.

Dividend Reinvestment Plan
Dividend Reinvestment Plan More.

2004 Earnings Expectations Clarified
CSL Limited today announced that the company was now in a position to clarify the Group’s overall earnings for the financial year 2004, following the purchase and ongoing integration of Aventis Behring. This follows on from CSL’s update to the market in May this year when the company said it was unable to provide an accurate earnings forecast for 2004. More.

CSL Appoints New Director
CSL today announced that Mr Maurice Renshaw had been appointed a Director and would join the CSL Board effective immediately. More.

S.A.F.E. Study confirms ALBUMEX can be used safely* in fluid resuscitation

CSL Limited today announced that the S.A.F.E. (Saline versus Albumin Fluid Evaluation) Study, published in the prestigious New England Journal of Medicine, proves conclusively that ALBUMEX (Human Albumin) can be used safely for the fluid resuscitation of patients in intensive care1. More.

CSL Completes Acquisition of Aventis Behring to create ZLB Behring
CSL Limited today announced the completion on March 31, 2004 of its acquisition of global plasma therapeutics business, Aventis Behring from Aventis SA. More.

CSL Announces Half Year Results
CSL Limited today announced its first half result for period ended 31 December 2003. More.

© 2017 CSL Limited